Advertisement

Brain Networks, Clinical Manifestations, and Neuroimaging of Cognitive Disorders

The Role of Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Other Advanced Neuroimaging Tests
  • Borna Bonakdarpour
    Correspondence
    Corresponding author. 300 East Superior Street, Tarry 8, Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Chicago, IL 60611.
    Affiliations
    Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine
    Search for articles by this author
  • Clara Takarabe
    Affiliations
    Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine
    Search for articles by this author
Published:October 18, 2022DOI:https://doi.org/10.1016/j.cger.2022.07.004

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cooper C.A.
        • Chahine L.M.
        Biomarkers in Prodromal Parkinson disease: a Qualitative review.
        J Int Neuropsychol Soc. 2016; 22: 956-967
        • Cohen A.D.
        • Landau S.M.
        • Snitz B.E.
        • et al.
        Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease.
        Mol Cell Neurosci. 2019; 97: 3-17
        • Desikan R.S.
        • Rafii M.S.
        • Brewer J.B.
        • et al.
        An expanded role for neuroimaging in the evaluation of memory impairment.
        AJNR Am J Neuroradiol. 2013; 34: 2075-2082
        • Young G.S.
        • Geschwind M.D.
        • Fischbein N.J.
        • et al.
        Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.
        AJNR Am J Neuroradiol. 2005; 26: 1551-1562
        • Runge V.M.
        • Aoki S.
        • Bradley Jr., W.G.
        • et al.
        Magnetic resonance imaging and computed tomography of the brain—50 Years of Innovation, with a Focus on the Future.
        Invest Radiol. 2015; 50: 551
        • Singhal T.
        • Narayanan T.K.
        • Jacobs M.P.
        • et al.
        11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI.
        J Nucl Med. 2012; 53: 1709-1715
        • Graff-Radford N.R.
        • Jones D.T.
        Normal Press Hydrocephalus. Continuum . 2019; 25: 165-186
        • Klunk W.E.
        • Engler H.
        • Nordberg A.
        • et al.
        Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B.
        Ann Neurol. 2004; 55: 306-319
        • Johnson K.A.
        • Minoshima S.
        • Bohnen N.I.
        • et al.
        Appropriate use criteria for amyloid PET: a report of the amyloid imaging task Force, the Society of nuclear Medicine and molecular imaging, and the Alzheimer’s association.
        Alzheimers Dement. 2013; 9: e.1-16
        • Wong D.F.
        • Rosenberg P.B.
        • Zhou Y.
        • et al.
        In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
        J Nucl Med. 2010; 51: 913-920
        • Carome M.
        • Wolfe S.
        Florbetapir-PET imaging and postmortem beta-amyloid pathology.
        JAMA. 2011; 305 ([author reply: 1857–8]): 1857
        • Clark C.M.
        • Schneider J.A.
        • Bedell B.J.
        • et al.
        Use of florbetapir-PET for imaging beta-amyloid pathology.
        JAMA. 2011; 305: 275-283
        • McKeith I.
        • O’Brien J.
        • Walker Z.
        • et al.
        Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
        Lancet Neurol. 2007; 6: 305-313
        • Nihashi T.
        • Ito K.
        • Terasawa T.
        Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis.
        Eur J Nucl Med Mol Imaging. 2020; 47: 1984-1997
        • Ilgin N.
        • Zubieta J.
        • Reich S.G.
        • et al.
        PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease.
        Neurology. 1999; 52: 1221-1226
        • Sakamoto F.
        • Shiraishi S.
        • Kitajima M.
        • et al.
        Diagnostic performance of 123I-FPCIT SPECT specific binding ratio in progressive supranuclear palsy: use of core clinical features and MRI for comparison.
        AJR Am J Roentgenol. 2020; 215: 1443-1448
        • Takaya S.
        • Sawamoto N.
        • Okada T.
        • et al.
        Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT.
        Parkinsonism Relat Disord. 2018; 47: 15-21
        • Seppi K.
        • Scherfler C.
        • Donnemiller E.
        • et al.
        Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.
        Arch Neurol. 2006; 63: 1154-1160
        • Booth T.C.
        • Nathan M.
        • Waldman A.D.
        • et al.
        The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.
        AJNR Am J Neuroradiol. 2015; 36: 229-235
        • Cilia R.
        • Rossi C.
        • Frosini D.
        • et al.
        Dopamine transporter SPECT imaging in corticobasal syndrome.
        PLoS One. 2011; 6e18301
        • Ogawa T.
        • Fujii S.
        • Kuya K.
        • et al.
        Role of neuroimaging on differentiation of Parkinson’s disease and its related diseases.
        Yonago Acta Med. 2018; 61: 145-155
        • Mesulam
        Aphasia, memory loss, and other focal cerebral disorders. Harrison’s Principles of Internal Medicine.
        21st edition. 2022 (in press)
        • Seeley W.W.
        • Menon V.
        • Schatzberg A.F.
        • et al.
        Dissociable intrinsic connectivity networks for salience processing and executive control.
        J Neurosci. 2007; 27: 2349-2356
        • Rabinovici G.D.
        • Stephens M.L.
        • Possin K.L.
        Executive dysfunction.
        Continuum. 2015; 21: 646-659
        • Mesulam M.
        Representation, inference, and transcendent encoding in neurocognitive networks of the human brain.
        Ann Neurol. 2008; 64: 367-378
        • Loscalzo J.
        • Fauci A.S.
        • Kasper D.L.
        • et al.
        Harrison’s principles of internal Medicine.
        McGraw Hill, New York2022
        • Capone P.M.
        • Bertelson J.A.
        • Ajtai B.
        Neuroimaging of normal pressure hydrocephalus and hydrocephalus.
        Neurol Clin. 2020; 38: 171-183
        • Faria A.V.
        • Pereira I.C.
        • Nanni L.
        Computerized tomography findings in Fahr’s syndrome.
        Arq Neuropsiquiatr. 2004; 62: 789-792
        • Johnson E.B.
        • Gregory S.
        Huntington’s disease: brain imaging in Huntington's disease.
        Prog Mol Biol Transl Sci. 2019; 165: 321-369
        • Staffaroni A.M.
        • Elahi F.M.
        • McDermott D.
        • et al.
        Neuroimaging in dementia.
        Semin Neurol. 2017; 37: 510-537
        • VandeVrede L.
        • Ljubenkov P.A.
        • Rojas J.C.
        • et al.
        Four-repeat tauopathies: current Management and Future treatments.
        Neurotherapeutics. 2020; 17: 1563-1581
        • Massey L.A.
        • Jäger H.R.
        • Paviour D.C.
        • et al.
        The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.
        Neurology. 2013; 80: 1856-1861
        • Geschwind M.D.
        Rapidly progressive dementia.
        Continuum. 2016; 22: 510-537
        • Collie D.A.
        • Sellar R.J.
        • Zeidler M.
        • et al.
        MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol.
        Clin Radiol. 2001; 56: 726-739
        • Murray M.E.
        • Graff-Radford N.R.
        • Ross O.A.
        • et al.
        Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study.
        Lancet Neurol. 2011; 10: 785-796
        • Langbaum J.B.S.
        • Chen K.
        • Lee W.
        • et al.
        Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
        Neuroimage. 2009; 45: 1107-1116
        • Kawachi T.
        • Ishii K.
        • Sakamoto S.
        • et al.
        Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease.
        Eur J Nucl Med Mol Imaging. 2006; 33: 801-809
        • Basso M.R.
        • Whiteside D.
        • Combs D.
        • et al.
        Memory in multiple sclerosis: a reappraisal using the item specific deficit approach.
        Neuropsychology. 2021; 35: 207-219
        • Syc S.B.
        • Harrison D.M.
        • Saidha S.
        • et al.
        Quantitative MRI demonstrates abnormality of the fornix and cingulum in multiple sclerosis.
        Mult Scler Int. 2013; 2013: 838719
        • Sullivan E.V.
        • Pfefferbaum A.
        Neuroimaging of the Wernicke-Korsakoff syndrome.
        Alcohol Alcohol. 2009; 44: 155-165
        • Helm-Estabrooks N.
        • Albert M.L.
        • Nicholas M.
        Manual of aphasia and aphasia Therapy.
        PRO-ED, New York2014
        • Ellis C.
        • Urban S.
        Age and aphasia: a review of presence, type, recovery and clinical outcomes.
        Top Stroke Rehabil. 2016; 23: 430-439
        • Wardlaw J.M.
        • Smith C.
        • Dichgans M.
        Small vessel disease: mechanisms and clinical implications.
        Lancet Neurol. 2019; 18: 684-696
        • Jiang L.
        • Cai X.
        • Yao D.
        • et al.
        Association of inflammatory markers with cerebral small vessel disease in community-based population.
        J Neuroinflammation. 2022; 19: 106
        • Oboudiyat C.
        • Bigio E.H.
        • Bonakdarpour B.
        • et al.
        Diffuse leukoencephalopathy with spheroids presenting as primary progressive aphasia.
        Neurology. 2015; 85: 652-653
        • Balash Y.
        • Korczyn A.D.
        • Khmelev N.
        • et al.
        Creutzfeldt-jakob and vascular brain diseases: their Overlap and relationships.
        Front Neurol. 2021; 12: 613991
        • Mahboob H.B.
        • Kaokaf K.H.
        • Gonda J.M.
        Creutzfeldt-jakob disease presenting as expressive aphasia and nonconvulsive Status epilepticus.
        Case Rep Crit Care. 2018; 2018: 5053175
        • Apple A.C.
        • Mao Q.
        • Bigio E.
        • et al.
        Sleep talking and primary progressive aphasia: case study and autopsy findings in a patient with logopenic primary progressive aphasia and dementia with Lewy bodies.
        BMJ Case Rep. 2019; 12https://doi.org/10.1136/bcr-2018-228938
        • Watanabe H.
        • Ikeda M.
        • Mori E.
        Primary progressive aphasia as a Prodromal state of dementia with Lewy bodies: a case report.
        Front Neurol. 2020; 11https://doi.org/10.3389/fneur.2020.00049
        • Mendez M.F.
        Early-onset Alzheimer disease and its variants.
        Continuum. 2019; 25: 34-51
        • Manners D.N.
        • Parchi P.
        • Tonon C.
        • et al.
        Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease.
        Neurology. 2009; 72: 1425-1431
        • Pelak V.S.
        The clinical approach to the identification of higher-order visual dysfunction in neurodegenerative disease.
        Curr Neurol Neurosci Rep. 2022; 22: 229-242